News Detail
NEW DELHI, 16 OCT 2024: The Indian Patent Office has rejected the grant of a patent for dolutegravir, a crucial HIV drug marketed by Viiv Healthcare, facilitating the entry of generics and expanding access to affordable, life-saving treatment. The decision, announced after a contentio......
View Details
View Details
Source : The Times of India
Today news
Google news
Breaking news
Viiv Healthcare
patent
Indian Patent Office
HIV drug
generics
evergreening
dolutegravir
Related News
- Raid on unlicensed medical store in Sakchi: Large stock of banned medicines found (16-10-2024)
- Mitskind Healthcare gifts 15 cars to employees ahead of Diwali (16-10-2024)
- Two shopkeepers arrested selling fake goods of a renowned company, case registered (16-10-2024)
- DTAB recommends to do away with toxicity studies for intravenous infusions and injectables (16-10-2024)
- Delhi-Gujarat haul: Drugs brought from S America, purified in Ankleshwar (16-10-2024)
- FDA Raids Unlicensed Factory Manufacturing Artificial Teeth (15-10-2024)
- Supreme Court rejects plea alleging side effects of COVID-19 vaccines (15-10-2024)
- Consumer affairs minister slams air purifier firms for false claims (15-10-2024)
- Union Health Secretary addresses Annual India Leadership Summit (15-10-2024)
- Open sale of painkillers sparks addiction concerns (15-10-2024)